Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10501446" target="_blank" >RIV/00064203:_____/25:10501446 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10501446

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cuCrD~Qnwi" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cuCrD~Qnwi</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hem3.70206" target="_blank" >10.1002/hem3.70206</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy

Popis výsledku v původním jazyce

To improve the outcome of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients, the AIEOP-BFM ALL 2009 trial modified T-ALL stratification and treatment based on AIEOP-BFM ALL 2000 and other pediatric ALL groups&apos; results. This report aims to describe the outcome of T-ALL patients in trial AIEOP-BFM ALL 2009 and evaluate prognostic features defined within the end of induction (EOI) therapy, for future protocols stratification and interventions. From 06/2010 to 02/2017, 872 T-ALL patients, aged 1-17, were enrolled. High risk (HR) criteria were prednisone poor response (PPR), Day 15 flow cytometry minimal residual disease (MRD) &gt;= 10%, no complete remission at EOI, or polymerase chain reaction (PCR)-MRD &gt;= 5 x 10(-4) at end of consolidation (EOC). Three Cox regression models on event-free survival (EFS) evaluated prognostic factors. Overall, 5-year EFS and survival were 79.9% +- 1.4% and 84.9% +- 1.2% with cumulative incidence of relapse (CIR) and death of 13.0% +- 1.2% and 5.9% +- 0.8%. Five-year EFS and CIR were 86.8% +- 1.6% and 8.7% +- 1.3% in non-HR patients (n = 470); 71.9% +- 2.3% and 18.0% +- 1.9% in HR patients (n = 402). High PCR-MRD levels at EOI and EOC were prognostic in all models, with EOC-MRD &gt;= 5 x 10(-3) related to a hazard ratio of 6.22 (P &lt; 0.001). When a model considered factors identified at EOI only, central nervous system (CNS)3 (hazard ratio = 2.3, P &lt; 0.001), PPR (hazard ratio = 1.74, P = 0.02), and high EOI-MRD (hazard ratio 4.71 for &gt;=5 x 10(-2) vs. negative, P &lt; 0.001) significantly impacted EFS. Results of T-ALL patients in AIEOP-BFM ALL 2009 were favorable. While EOC-MRD remained the strongest prognostic predictor, PPR, CNS3 disease, and EOI-MRD showed relevant prognostic value, with CNS3 and EOI-MRD &gt;= 5 x 10(-2) being candidate criteria for early stratification and intervention modifications.

Název v anglickém jazyce

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy

Popis výsledku anglicky

To improve the outcome of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients, the AIEOP-BFM ALL 2009 trial modified T-ALL stratification and treatment based on AIEOP-BFM ALL 2000 and other pediatric ALL groups&apos; results. This report aims to describe the outcome of T-ALL patients in trial AIEOP-BFM ALL 2009 and evaluate prognostic features defined within the end of induction (EOI) therapy, for future protocols stratification and interventions. From 06/2010 to 02/2017, 872 T-ALL patients, aged 1-17, were enrolled. High risk (HR) criteria were prednisone poor response (PPR), Day 15 flow cytometry minimal residual disease (MRD) &gt;= 10%, no complete remission at EOI, or polymerase chain reaction (PCR)-MRD &gt;= 5 x 10(-4) at end of consolidation (EOC). Three Cox regression models on event-free survival (EFS) evaluated prognostic factors. Overall, 5-year EFS and survival were 79.9% +- 1.4% and 84.9% +- 1.2% with cumulative incidence of relapse (CIR) and death of 13.0% +- 1.2% and 5.9% +- 0.8%. Five-year EFS and CIR were 86.8% +- 1.6% and 8.7% +- 1.3% in non-HR patients (n = 470); 71.9% +- 2.3% and 18.0% +- 1.9% in HR patients (n = 402). High PCR-MRD levels at EOI and EOC were prognostic in all models, with EOC-MRD &gt;= 5 x 10(-3) related to a hazard ratio of 6.22 (P &lt; 0.001). When a model considered factors identified at EOI only, central nervous system (CNS)3 (hazard ratio = 2.3, P &lt; 0.001), PPR (hazard ratio = 1.74, P = 0.02), and high EOI-MRD (hazard ratio 4.71 for &gt;=5 x 10(-2) vs. negative, P &lt; 0.001) significantly impacted EFS. Results of T-ALL patients in AIEOP-BFM ALL 2009 were favorable. While EOC-MRD remained the strongest prognostic predictor, PPR, CNS3 disease, and EOI-MRD showed relevant prognostic value, with CNS3 and EOI-MRD &gt;= 5 x 10(-2) being candidate criteria for early stratification and intervention modifications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HemaSphere

ISSN

2572-9241

e-ISSN

2572-9241

Svazek periodika

9

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

e70206

Kód UT WoS článku

001565324400001

EID výsledku v databázi Scopus

2-s2.0-105014736424